Get App
you are here: HomeNewsBusiness
Last Updated : Apr 30, 2020 01:17 PM IST | Source: PTI

Lupin gets inspection closure report from USFDA for Pithampur plant

The inspection for the facility was conducted by the US health regulator between February 3 and February 11, 2020, and concluded with two observations, the Mumbai-based company said.


Drug maker Lupin on Thursday said the US health regulator has closed the inspection of its manufacturing facility in Pithampur, Madhya Pradesh.

The inspection for the facility was conducted by the US health regulator between February 3 and February 11, 2020, and concluded with two observations, the Mumbai-based company said.

The company has received the establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-1 facility, Lupin said.

The USFDA issues an EIR to a company when an inspection is satisfactorily closed.

Lupin Managing Director Nilesh Gupta said the company has received the EIR for the plant with Voluntary Action Indicated (VAI) status.

"Continuous improvement of our quality and compliance standards across all our manufacturing sites is a key focus area for the company and we are committed to working with the USFDA to manufacture and supply products of the highest quality from all our manufacturing sites," he added.

Also read: Market bit out of sync with economy; feel comfortable as a long-term investor: Hugh Young

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.


First Anniversary Offer: Subscribe to Moneycontrol PRO’s annual plan for ₹1/- per day for the first year and claim exclusive benefits worth ₹20,000. Coupon code: PRO365

First Published on Apr 30, 2020 01:10 pm
Sections
Follow us on